Date: 2014-05-06
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of preclinical development
Company: Apitope International (UK-Belgium)
Product: ATX-F8-117
Action mechanism:
Disease: factor VIII intolerance
Therapeutic area: Hematologic diseases - Genetic diseases - Rare diseases
Country:
Trial details:
Latest
news: * On May 6, 2014, Apitope, a drug discovery and development company focused on disease-modifying peptide treatments for the underlying cause of autoimmune and allergic diseases, announced that its peptide therapy for the treatment of Factor VIII intolerance, ATX-F8-117, has formally entered preclinical development. Apitope has, through its patented discovery platform, completed the research work to confirm that the two peptides in ATX-F8-117, derived from Factor VIII, have the potential to treat and prevent inactivating alloantibody development in haemophilia A patients treated with Factor VIII. Haemophilia A patients are normally treated with Factor VIII to help with the clotting of their blood. However, since these patients’ immune systems have had no or low exposure to normal FVIII, they are often not fully tolerant to the Factor VIII used to treat their condition. As a consequence, up to 30 % of these patients develop Factor VIII inhibitor antibodies. The development of these antibodies is the most serious complication that can develop and significantly limits the treatment of this disorder as well as increasing the cost burden. Apitope’s R&D portfolio currently comprises seven programmes in clinical and preclinical phases, targeting multiple sclerosis, Factor VIII intolerance, uveitis, and the thyroid-related autoimmune condition, Graves’ disease.
